Takeda Pharmaceutical Co. and Amylin Pharmaceuticals have mutually terminated their worldwide agreement to co-develop and commercialize compounds for obesity. The pact began in October 2009, . The companies announced in August 2011 their decision to discontinue the development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity. That joint decision was based on a commercial reassessment of the pramlintide/metreleptin program, which had been in Phase I...